Directorio

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

We are doing this study to find out if an experimental drug called XC001 (the study drug) is an effective option for people who have angina that is caused by coronary artery disease. We want to know if the study drug can provide relief when common, approved therapies have failed to do so. The study drug is made using an adenovirus (one of the causes of the common cold). The adenovirus in the study drug is genetically altered so it is able to deliver a protein called VEGF (vascular endothelial growth factor) to the heart and potentially spur the growth of new blood vessels.

In this study, people will get a new kind of eye transplant. They'll be randomly chosen (like flipping a coin) to get either a special treated cornea or a regular one. Doctors will check on them for 2 years after the transplant to see how they're doing and to watch for any side effects.

We are doing this study to evaluate an experimental technology called the Reprieve Decongestion Management System (the study device) for heart failure patients with fluid overload. The study device is designed to help people with heart failure feel better by removing extra fluid from their body quickly. The device is programmed to deliver an appropriate amount of medication at the right time to help people shed extra fluid through urination. We want to know if this device works better than the standard treatment. The standard treatment is to prescribe diuretics (medication to increase urination) at a specified dose and dosage schedule.

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.